Paris, France-based cardiology specialist Corteria Pharmaceuticals has announced the appointment of Dr Mark Pruzanski, as chairman of its board of directors. 6 January 2024
UK-based Arecor Therapeutics has announced the appointment of Dr Helen Parris as senior vice president, commercial and general manager of Tetris Pharma. 3 January 2024
Vicore Pharma, a Swedish pharma company seeking to unlock the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), has announced that Bertil Lindmark will join as chief medical officer. 18 December 2023
Cancer Research UK has appointed industry veteran Dr Lars Erwig as the new director for its Centre for Drug Development, the world's only charity-funded drug development facility. 12 December 2023
Shorla Oncology, a privately-held, female founded US-Ireland pharmaceutical company, announced today that it has appointed Rayna Sethi Herman as chief commercial officer. 8 December 2023
French independent pharma major Servier today announced the appointment of Nicolas Garnier as chief patient officer, effective from December 4. 5 December 2023
US ophthalmic drug developer Ocuphire Pharma has announced the appointment of Joseph (Joe) Schachle into the newly created role of chief operating officer (COO), effective today. 27 November 2023
US clinical-stage liver disease specialist Madrigal Pharmaceuticals’ shares gained 1.8% to $138.84 on Friday, as it announced new data from the Phase III MAESTRO-NASH trial demonstrating broad treatment effects of resmetirom. 13 November 2023
Poolbeg Pharma has recruited three new members of its leadership team from Amryt Pharma, a fellow Anglo-Irish drugmaker with the same co-founder that was recently acquired by privately-held Italian drugmaker Chiesi. 10 November 2023
American biopharma company Vertex Pharmaceuticals has announced strong third quarter financial results and raised its guidance for product revenues in 2023. 7 November 2023
Thomas Cueni, the director general of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and secretary of the Biopharmaceutical CEO Roundtable (BCR), is set to retire in April 2024. 6 November 2023
US ophthalmic drug developer Ocuphire Pharma has appointed Dr George Magrath, as chief executive and member of the board of directors, effective today. 2 November 2023
Privately-held Italian drugmaker Chiesi today announced the appointment of Ralph Blom as the general manager for Chiesi Limited (covering the UK and Ireland), beginning January 2024. 30 October 2023
German active pharmaceutical ingredient (API) manufacturer Axplora has appointed Stephan Haitz as president of the Novasep business unit. 19 October 2023
Privately-held Danish dermatology specialist LEO Pharma has named Professor Alexander Egeberg, a globally recognized dermatologist and top key opinion leader as the company’s new vice president, head of global medical affairs. 9 October 2023
Rare diseases specialist Swedish Orphan Biovitrum, also known as Sobi, today announced that Lydia Abad-Franch has been appointed as senior vice president, head of research, development and medical affairs (RDMA), and chief medical office, a role which she has held on an interim basis since June. 5 October 2023
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announces the appointment of Nicholas Ostrout, as vice president of corporate development and strategy. 7 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
Novocure (Nasdaq: NVCR) has announced that chief executive Asaf Danziger will retire at the end of 2024, with current chief financial officer Ashley Cordova set to succeed him as CEO. 4 September 2024
Lykos Therapeutics has announced a reorganization to best support the company as it works to address the resubmission of its new drug application (NDA) for midomafetamine capsules for the treatment of post-traumatic stress disorder (PTSD) in adults. 16 August 2024
German infectious disease specialist AiCuris Anti-infective Cures has announced the appointment of Cynthia Wat as chief medical officer (CMO). 30 July 2024
Ophirex, a registered public benefit corporation developing an oral field treatment to address the global unmet medical needs of snakebite victims, has announced the appointment of Jeremy Gowler as chief executive. 15 July 2024
US drugmaker AbbVie has announced that Roopal Thakkar, who currently serves as senior vice president, chief medical officer, global therapeutics, has been appointed to the position of executive vice president, research and development, and chief scientific officer (CSO). 10 July 2024